Patient Characteristics
| Variable | No cardiac death (n = 2,646) | Cardiac death (n = 137) | All patients (n = 2,783) | P |
| Demographic | ||||
| Age (y) | 64.3 [55.8–74.6] | 74.6 [63.7–81.4] | 64.8 [56.1–75.2] | <0.0001 |
| Male sex | 1,242 (46.9%) | 91 (66.4%) | 1,333 (47.9%) | <0.0001 |
| Hispanic | 300 (11.3%) | 3 (2.2%) | 303 (10.9%) | 0.0002 |
| Race | 0.06 | |||
| White | 1,662 (62.8%) | 100 (73.0%) | 1,762 (63.3%) | |
| Black | 436 (16.5%) | 17 (12.4%) | 453 (16.3%) | |
| Other/unknown | 548 (20.7%) | 20 (14.6%) | 568 (20.4%) | |
| Risk factor | ||||
| Body mass index (kg/m2) | 29 [25.1–34.7] | 26.4 [23–30.4] | 28.8 [25.1–34.4] | <0.0001 |
| ≥30 kg/m2 | 1,167 (44.1%) | 37 (27.0%) | 1,204 (43.3%) | <0.0001 |
| Hypertension | 2,154 (81.4%) | 117 (85.4%) | 2,271 (81.6%) | 0.26 |
| Dyslipidemia | 1,756 (66.4%) | 97 (70.8%) | 1,853 (66.6%) | 0.31 |
| Diabetes | 940 (35.5%) | 68 (49.6%) | 1,008 (36.2%) | 0.001 |
| Family history of CAD | 723 (27.3%) | 33 (24.1%) | 756 (27.2%) | 0.43 |
| Tobacco use | 276 (10.4%) | 18 (13.1%) | 294 (10.6%) | 0.06 |
| Dialysis | 118 (4.5%) | 15 (11.0%) | 133 (4.8%) | 0.003 |
| Indication | ||||
| Chest pain | 1,268 (47.9%) | 38 (27.7%) | 1,306 (46.9%) | <0.0001 |
| Dyspnea | 791 (29.9%) | 61 (44.5%) | 852 (30.6%) | 0.0006 |
| Post–myocardial infarction | 223 (8.4%) | 28 (20.4%) | 251 (9.0%) | < 0.0001 |
| Preoperative | 380 (14.4%) | 28 (20.4%) | 408 (14.7%) | 0.06 |
| Cardiovascular history | ||||
| Any prior CAD | 1,070 (40.4%) | 105 (76.6%) | 1,175 (42.2%) | <0.0001 |
| Recent myocardial infarction (≤30 d) | 279 (10.5%) | 37 (27.0%) | 316 (11.4%) | <0.0001 |
| Remote myocardial infarction (>30 d) | 462 (17.5%) | 49 (35.8%) | 511 (18.4%) | <0.0001 |
| Prior percutaneous coronary intervention | 565 (21.4%) | 47 (34.3%) | 612 (22.0%) | 0.0007 |
| Prior coronary artery bypass grafting | 317 (12.0%) | 52 (38.0%) | 369 (13.3%) | 0.0007 |
| Congestive heart failure | 115 (4.4%) | 28 (20.4%) | 143 (5.1%) | <0.0001 |
| Early revascularization (≤90 d post-PET) | 217 (8.2%) | 18 (13.1%) | 235 (8.4%) | 0.0564 |
| Stress protocol | <0.0001 | |||
| Adenosine | 205 (7.8%) | 11 (8.0%) | 216 (7.8%) | |
| Dipyridamole | 1,280 (48.4%) | 96 (70.1%) | 1376 (49.4%) | |
| Dobutamine | 115 (4.4%) | 9 (6.6%) | 124 (4.5%) | |
| Regadenoson | 1,046 (39.5%) | 21 (15.3%) | 1,067 (38.3%) | |
| Imaging parameters | ||||
| Rest left ventricular ejection fraction (%) | 59 [49–66] | 39 [27–54] | 58 [48–66] | < 0.0001 |
| Stress-induced ↑left ventricular ejection fraction | 2,060 (77.9%) | 87 (63.5%) | 2,147 (77.2%) | 0.0002 |
| Scar + ischemic myocardium (%) | 0 [0–10.3] | 16.2 [4.4–35.3] | 0 [0–10.3] | <0.0001 |
| Ischemic myocardium (%) | 0 [0–4.4] | 4.4 [0–10.3] | 0 [0–5.9] | <0.0001 |
| Global MFR | 1.76 [1.37–2.25] | 1.31 [1.12–1.56] | 1.73 [1.34–2.22] | <0.0001 |
| Stress global MBF (mL/min/g) | 1.82 [1.25–2.54] | 1.26 [0.92–1.82] | 1.80 [1.23–2.52] | <0.0001 |
| Rest global MBF (mL/min/g) | 1.01 [0.79–1.33] | 1.00 [0.75–1.34] | 1.01 [0.78–1.33] | 0.41 |
Numbers presented are median [interquartile range] for continuous variables and number (%) for binary and categorical variables.